Bronchodilator reversibility in chronic obstructive pulmonary disease: Use and limitations

The Lancet Respiratory Medicine

Volumn 1, Issue 7, 2013, Pages 564-573

  Calverley, Peter M A ^a,b   Albert, Paul ^b   Walker, Paul P ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; IPRATROPIUM BROMIDE; ISOPRENALINE; SALBUTAMOL;

BRONCHODILATATION; BRONCHODILATOR REVERSIBILITY TEST; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INTERMITTENT POSITIVE PRESSURE VENTILATION; LUNG FUNCTION; LUNG VOLUME; PATIENT COMPLIANCE; PATIENT IDENTIFICATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY TRACT EXAMINATION; REVIEW; SPIROMETRY; TREATMENT RESPONSE; BRONCHIAL HYPERREACTIVITY; DOSE RESPONSE; DRUG EFFECTS; FORECASTING; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TIME; TREATMENT OUTCOME; VITAL CAPACITY;

BRONCHIAL HYPERREACTIVITY; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FORCED EXPIRATORY VOLUME; FORECASTING; HUMANS; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84883466304     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(13)70086-9     Document Type: Review

References (73)

1. McDonough JE, Yuan R, Suzuki M, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med 2011, 365:1567-1575.
2. Hogg JC Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004, 364:709-721.
3. O'Donnell DE, Webb KA Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. Am Rev Respir Dis 1993, 148:1351-1357.
4. Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Morkve O Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 2002, 20:1117-1122.
5. Mannino DM, Watt G, Hole D, et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J 2006, 27:627-643.
6. 1/FVC ratio reduces the misclassification of airway obstruction. Thorax 2008, 63:1046-1051.
7. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013, 187:347-365.
8. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007, 370:741-750.
9. Menezes AM, Perez-Padilla R, Jardim JR, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005, 366:1875-1881.
10. Nisar M, Earis JE, Pearson MG, Calverley PM Acute bronchodilator trials in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992, 146:555-559.
11. Kahneman DK Thinking Fast and Slow 2011, Farrar, Strauss and Groux, New York.
12. Eliasson O, Degraff AC The use of criteria for reversibility and obstruction to define patient groups for bronchodilator trials. Influence of clinical diagnosis, spirometric, and anthropometric variables. Am Rev Respir Dis 1985, 132:858-864.
13. Hanania NA, Celli BR, Donohue JF, Martin UJ Bronchodilator reversibility in COPD. Chest 2011, 140:1055-1063.
14. Perez-Padilla R, Hallal PC, Vazquez-Garcia JC, et al. Impact of bronchodilator use on the prevalence of COPD in population-based samples. COPD 2007, 4:113-120.
15. Enright PL, Connett JE, Kanner RE, Johnson LR, Lee WW Spirometry in the Lung Health Study: II. Determinants of short-term intraindividual variability. Am J Respir Crit Care Med 1995, 151:406-411.
16. 1 response to bronchodilation in an adult urban population. Chest 2008, 134:387-393.
17. Tan WC, Vollmer WM, Lamprecht B, et al. Worldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease study. Thorax 2012, 67:718-726.
18. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005, 26:948-968.
19. Albert P, Agusti A, Edwards L, et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax 2012, 67:701-708.
20. Intermittent positive pressure breathing therapy of chronic obstructive pulmonary disease. A clinical trial. Ann Intern Med 1983, 99:612-620. [No authors listed].
21. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993, 16:5-40.
22. Miller MR, Hankinson J, Brusasco V, et al. ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 2005, 26:319-338.
23. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003, 361:449-456.
24. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003, 22:912-919.
25. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002, 166:1084-1091.
26. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005, 143:317-326.
27. In chronic obtructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994, 105:1411-1419. COMBIVENT Inhalation Aerosol Study Group.
28. Nisar M, Walshaw M, Earis JE, Pearson MG, Calverley PM Assessment of reversibility of airway obstruction in patients with chronic obstructive airways disease. Thorax 1990, 45:190-194.
29. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax 2003, 58:654-658.
30. Palmer LJ, Celedon JC, Chapman HA, Speizer FE, Weiss ST, Silverman EK Genome-wide linkage analysis of bronchodilator responsiveness and post-bronchodilator spirometric phenotypes in chronic obstructive pulmonary disease. Hum Mol Genet 2003, 12:1199-1210.
31. Anthonisen NR, Wright EC Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986, 133:814-819.
32. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011, 365:1184-1192.
33. Anthonisen NR, Lindgren PG, Tashkin DP, Kanner RE, Scanlon PD, Connett JE Bronchodilator response in the lung health study over 11 yrs. Eur Respir J 2005, 26:45-51.
34. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003, 58:659-664.
35. Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008, 31:742-750.
36. Han MK, Wise R, Mumford J, et al. Prevalence and clinical correlates of bronchoreversibility in severe emphysema. Eur Respir J 2010, 35:1048-1056.
37. Hanania NA, Sharafkhaneh A, Celli B, et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res 2011, 12:6.
38. Montes de Oca M, Tálamo C, Perez-Padilla R, et al. Use of respiratory medication in five Latin American cities: the PLATINO study. Pulm Pharmacol Ther 2008, 21:788-793. PLATINO Team.
39. Hadcroft J, Calverley PM Alternative methods for assessing bronchodilator reversibility in chronic obstructive pulmonary disease. Thorax 2001, 56:713-720.
40. Gross NJ, Petty TL, Friedman M, Skorodin MS, Silvers GW, Donohue JF Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. A three-center study. Am Rev Respir Dis 1989, 139:1188-1191.
41. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997, 112:1514-1521. The COMBIVENT Inhalation Solution Study Group.
42. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554.
43. O'Reilly J, Jones MM, Parnham J, Lovibond K, Rudolf M Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance. BMJ 2010, published online June 25. 10.1136/bmj.c3134.
44. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000, 356:1480-1485.
45. Hansen EF, Phanareth K, Laursen LC, Kok-Jensen A, Dirksen A Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 159:1267-1271.
46. Albert P, Calverley P A PEACE-ful solution to COPD exacerbations?. Lancet 2008, 371:1975-1976.
47. Koulouris NG, Valta P, Lavoie A, et al. A simple method to detect expiratory flow limitation during spontaneous breathing. Eur Respir J 1995, 8:306-313.
48. Calverley PM, Koulouris NG Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology. Eur Respir J 2005, 25:186-199.
49. Crim C, Celli B, Edwards LD, et al. Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results. Respir Med 2011, 105:1069-1078.
50. Dellaca RL, Pompilio PP, Walker PP, Duffy N, Pedotti A, Calverley PM Effect of bronchodilation on expiratory flow limitation and resting lung mechanics in COPD. Eur Respir J 2009, 33:1329-1337.
51. Tantucci C, Duguet A, Similowski T, Zelter M, Derenne JP, Milic-Emili J Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J 1998, 12:799-804.
52. Laveneziana P, Webb KA, Ora J, Wadell K, O'Donnell DE Evolution of dyspnea during exercise in chronic obstructive pulmonary disease: impact of critical volume constraints. Am J Respir Crit Care Med 2011, 184:1367-1373.
53. O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004, 24:86-94.
54. Hay JG, Stone P, Carter J, et al. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 1992, 5:659-664.
55. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789.
56. O'Donnell DE, Lam M, Webb KA Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 160:542-549.
57. Newton MF, O'Donnell DE, Forkert L Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002, 121:1042-1050.
58. Walker PP, Calverley PM The volumetric response to bronchodilators in stable chronic obstructive pulmonary disease. COPD 2008, 5:147-152.
59. Cerveri I, Dore R, Corsico A, et al. Assessment of emphysema in COPD: a functional and radiologic study. Chest 2004, 125:1714-1718.
60. Gross NJ, Co E, Skorodin MS Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. Chest 1989, 96:984-987.
61. Di Stefano A, Capelli A, Lusuardi M, et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998, 158:1277-1285.
62. Cosio MG, Saetta M Evasion of COPD in smokers: at what price?. Eur Respir J 2012, 39:1298-1303.
63. Ballarin A, Bazzan E, Zenteno RH, et al. Mast cell infiltration discriminates between histopathological phenotypes of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 186:233-239.
64. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005, 26:319-338.
65. 1 and bronchodilator responsiveness in patients with obstructive ventilatory defects. Thorax 1987, 42:487-490.
66. Frey U, Brodbeck T, Majumdar A, et al. Risk of severe asthma episodes predicted from fluctuation analysis of airway function. Nature 2005, 438:667-670.
67. Frey U, Suki B Complexity of chronic asthma and chronic obstructive pulmonary disease: implications for risk assessment, and disease progression and control. Lancet 2008, 372:1088-1099.
68. Hansen EF, Vestbo J Bronchodilator reversibility in COPD: the roguish but harmless little brother of airway hyperresponsiveness?. Eur Respir J 2005, 26:6-7.
69. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002, 346:1699-1705.
70. Moreno RH, Hogg JC, Pare PD Mechanics of airway narrowing. Am Rev Respir Dis 1986, 133:1171-1180.
71. Drummond MB, Hansel NN, Connett JE, Scanlon PD, Tashkin DP, Wise RA Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 185:1301-1306.
72. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, Bethke TD Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005, 366:563-571.
73. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374:685-694.